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Answer to the ECG Quiz 
 
The pacemaker is functioning properly. This type 
of pacemaker has the AAI – safer algorithm 
incorporated. Based on this algorithm the device paces 
in AAI mode in the absence of AV block or in the 
presence of relatively accepatable episodes of first or 
second degree AV block. On the other hand, in the 
presence of marked AV conduction disturbances it 
switches to DDD mode. In this particular example, the 
device is using the criterion of the detection of two 
consecutive atrial events without intrinsic ventricular 
response (arrows). After this 2 blocked atrial 
depolarizations the pacemaker starts pacing in DDD 
mode. Note the shorter initial AV interval in the post-
AAI DDD sequence. This is a programmable parameter 
aiming to minimize the total duration of the ventricular 
pause.   
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Medtronic informs that a software problem has 
been noticed in the following models: Consulta CRT-D, 
Secura DR/VR, Concerto II CRT-D, Virtuoso II DR/VR, 
Maximo II CRT-D, Maximo IIDR/VR. By April, 19 
2010 Medtronic has received 5 confirmed reports from 
144000 devices none of them associated with adverse 
effects of any kind. A particular sequence of the 
following 3 facts must take place within a few ms to 
cause this problem.  
1. The high voltage capacitors obtain the programmed 
energy (termination of charge) 
2. Battery voltage measurement is in progress and  
3. The ventricular tachyarrhythmia is self-terminated 
and the subsequent therapy delivery is postponed.  
In that case, all future high voltage therapies would 
have an elongated charge time or would fail to deliver 
due to charge circuit time-out. The alert systems of the 
devices will notify the patients to seek medical 
attention and this problem will be fixed with a new 
software installed. The possibility of this malfunction is 
estimated about 1/27000 devices per year and the 
possibility of a patient needing therapy before the 
device alert is activated is about 1/291000 per year. 
 
Medtronic since September 2010 is updating the 
software of the EnRythm pacemaker and the telemetry 
device to correct certain problems concerning the 
battery to avoid loss of function in an estimated 0.08% 
of the patients. In short, the elective replacement 
indicator (ERI) changes from <2.59V to <2.81V and 
new criteria for the ERI determination have been 
endorsed. These modifications will shorten the 
pacemaker lifetime by 10-15%.  
 
On October 2010 Medtronic notes that regarding 
the leads Sprint Quattro 6935 and 6947, over-retraction 
of the helix during the initial implant or repositioning 
may result to inability to extend the helix. There have 
been 193 reports out of an estimated size of 154000 
leads used worldwide. This malfunction does not 
impair the performance of successfully placed leads. 
 
Medtronic has also informed that the multi-
channel Radio-Frequency generator GENius 990018 
may interact with implanted cardiac devices and cause 
high frequency signals in the atrial or ventricular lead 
leading to inappropriate shocks. By October 27, 2010 
Medtronic has received 4 confirmed and 1 unconfirmed 
reports out of 1000 patients with implanted device who 
underwent ablation using this particular system. In two 
of them external defibrillation was required. No deaths 
have been recorded. 
 
From St. Jude Medical comes a report regarding 
the performance of the Riata and Riata ST endocardial 
ICD lead models 1560, 1561, 1562, 1570, 1571, 1572, 
1580, 1581, 1582, 1590, 1591, 1592, 7000, 7001, 7002, 
7010, 7011, 7040, 7041, 7042. These leads use silicone 
as insulation material, which is known from the 
literature to be vulnerable to abrasion, although it is the 
most commonly used. The above-mentioned models 
have an abrasion rate of 0.49% over 9 years of use, 
which can cause oversensing, undersensing, loss of 
capture, changes in impedance or failure to deliver 
therapy. The newer generation leads use the Optim 
insulation material which shows a reduction of abrasion 
–related observations by 80% at 44 months of follow-
up. The overall survival rate of patients with the new 
leads reaches 98.8% at 44 months, compared to 98.4% 
among the patients carrying the previous lead model. 
This difference may be attributed to the lower rate of 
abrasion.  
 
 
 
 
 
 
 
 
 
